OTCMKTS:ERFSF Eurofins Scient (ERFSF) Stock Price, News & Analysis $87.23 +0.05 (+0.05%) As of 03:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and TrendsShort Interest About Eurofins Scient Stock (OTCMKTS:ERFSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eurofins Scient alerts:Sign Up Key Stats Today's Range$84.88▼$88.4150-Day Range$77.79▼$91.3252-Week Range$64.95▼$92.97Volume281 shsAverage Volume1,387 shsMarket Capitalization$16.54 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Eurofins Scientific SE is an international laboratory testing and research services company headquartered in Luxembourg. The company provides analytical, scientific and diagnostic services to customers in the pharmaceutical, food, environmental, agricultural, consumer products and healthcare sectors. Its services include testing and quality control for food, water, soil, pharmaceuticals and consumer goods; environmental analysis; genomic and genetic testing; clinical diagnostics; and support for pharmaceutical and biotechnology research, development and manufacturing. Eurofins operates through a network of laboratories and service locations across Europe, North America, South America, Asia-Pacific and other international markets. Eurofins was founded in 1987 by Gilles Martin and initially focused on food authenticity testing. It has since expanded through organic growth and acquisitions into a broad provider of laboratory and scientific services. Gilles Martin serves as chief executive officer and chairman of the company’s board.AI Generated. May Contain Errors. Read More Eurofins Scient Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreERFSF MarketRank™: Eurofins Scient scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingHold Consensus RatingEurofins Scient has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageEurofins Scient has only been the subject of 1 research reports in the past 90 days.Read more about Eurofins Scient's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioEurofins Scient has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.15% of the float of Eurofins Scient has been sold short.Short Interest Ratio / Days to CoverEurofins Scient has a short interest ratio ("days to cover") of 138.12, which indicates bearish sentiment.Change versus previous monthShort interest in Eurofins Scient has recently increased by 0.57%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEurofins Scient does not currently pay a dividend.Dividend GrowthEurofins Scient does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.11 News SentimentEurofins Scient has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Eurofins Scient this week, compared to 2 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eurofins Scient insiders have not sold or bought any company stock.Percentage Held by InstitutionsEurofins Scient has minimal institutional ownership at this time.Read more about Eurofins Scient's insider trading history. Receive ERFSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eurofins Scient and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ERFSF Stock News HeadlinesEurofins Updates Voting Rights After Buybacks and Unit CancellationsOctober 6 at 11:10 AM | tipranks.comEurofins Scientific: Director/PDMR ShareholdingOctober 5 at 1:38 PM | businesswire.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 6 at 1:00 AM | Porter & Company (Ad)Eurofins Scientific SE: Director/PDMR ShareholdingOctober 2, 2026 | businesswire.comEurofins Sells MET Labs to UL Solutions to Refocus on Core Life-Science TestingOctober 2, 2026 | tipranks.comEurofins Scientific: Director/PDMR ShareholdingSeptember 29, 2026 | businesswire.comEurofins Scientific SE: Director/PDMR ShareholdingSeptember 21, 2026 | businesswire.comEurofins Steps Up Share Buy-Back Activity Across European Trading VenuesSeptember 21, 2026 | tipranks.comSee More Headlines ERFSF Stock Analysis - Frequently Asked Questions How have ERFSF shares performed this year? Eurofins Scient's stock was trading at $73.28 at the beginning of 2026. Since then, ERFSF shares have increased by 19.0% and is now trading at $87.2260. How do I buy shares of Eurofins Scient? Shares of ERFSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryN/A Current SymbolOTCMKTS:ERFSF Previous SymbolNASDAQ:ERFSF CIKN/A Webwww.eurofins.com Phone(522) 618-5320Fax352-2618-5331Employees65,000Year Founded1987Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.80 Current Ratio1.13 Quick Ratio1.07 Sales & Book Value Annual Sales$8.25 billion Price / Sales2.00 Cash Flow$8.08 per share Price / Cash Flow10.79 Book Value$27.31 per share Price / Book3.19Miscellaneous Outstanding Shares189,620,000Free FloatN/AMarket Cap$16.54 billion OptionableNot Optionable Beta0.54 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:ERFSF) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...Market Savvy | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredParisian Penthouse: $650 a month (and your own chauffeur)A penthouse apartment for 650 a month in one of the ritziest neighborhoods in the city, comparable to Manhatta...International Living | SponsoredTrump Once Threatened THIS Country (Not Iran)Trump recently threatened a major economy not Iran, Canada, Mexico, or China over a new law that could hurt on...Monument Traders Alliance | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eurofins Scient Please log in to your account or sign up in order to add this asset to your watchlist. Share Eurofins Scient With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.